Naslov
The effect of P2Y12 inhibitor pretreatment vs. no pretreatment on major bleeding among patients with NSTE-ACS: an updated meta-analysis and meta- regression pooling 41,548 patients from 11 studies

Autori
Borovac, Josip Anđelo ; D'Amario, Domenico ; Schwarz, Konstantin ; Bradarić, Anteo ; Božić, Joško ; Glavaš, Duška

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, prošireni sažetak, znanstveni

Izvornik
European Heart Journal Special Edition / Crea, Filippo - : Oxford University Press, 2021, 1207-1207

Skup
European Society of Cardiology Congress (ESC 2021)

Mjesto i datum
Online, 27.08.2021. - 30.08.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
acute coronary syndromes ; clopidogrel ; prasugrel ; ticagrelor ; percutaneous coronary intervention ; PCI ; pharmacotherapy ; hemorrhage ; heterogeneity ; medline ; guidelines ; drug-eluting stents ; receptors, purinergic p2y12 ; non-st-segment acute coronary syndromes ; NSTE-ACS ; bleeding ; 2y12 receptor antagonists ; european society of cardiology ; embase ; primary outcome measures ; pretreatment ; preloading ; loading ; NSTEMI ; unstable angina

Sažetak
Background: Recent European Society of Cardiology (ESC) guidelines for the management of non-ST elevation acute coronary syndromes (NSTE-ACS) do not recommend routine pretreatment with P2Y12 inhibitors in patients in whom coronary anatomy is not known and an early invasive management is planned. Purpose: To investigate the impact of P2Y12 pretreatment vs. no pretreatment on short-term major bleeding events among patients with NSTE- ACS. Methods: MEDLINE and EMBASE databases were systematically searched to find interventional or observational studies that investigated the use of P2Y12 inhibitors as a pretreatment vs. no pretreatment in NSTE-ACS population. Studies that reported major bleeding events, as adjudicated by study' investigators, during hospitalization or within 30 days since randomization were included. Random-effects meta-analysis was performed with prespecified subgroup analysis concerning more potent P2Y12 inhibitor use and drug-eluting stent (DES) uptake >50%. For the primary analysis, the odds ratio (OR) with 95% confidence intervals (95% CI) were reported. Heterogeneity across studies was inspected by I2 statistic. Meta-regression was performed to assess potential interaction of variables including percutaneous coronary intervention (PCI) receipt, NSTE-ACS subtype, DES uptake >50%, and potent P2Y12 inhibitor use with the primary outcome. Results: Eleven studies that provided data on major bleeding were included (6 randomized clinical trials, 4 registry-based studies, and 1 prespecified analysis of an RCT) accumulating a total of 41, 548 patients with pooled 1366 major bleeding events (871 in the pretreatment and 495 in the no-pretreatment group). Most of the studies were older than 10 years and used clopidogrel as a pretreatment while the average rate of PCI receipt was 78.2%. Low-to-moderate heterogeneity was detected across studies. Pretreatment with P2Y12 inhibitors increased the likelihood of major bleeding (OR 1.245, 95% CI 1.092–1.419) across all studies analyzed while in contemporary NSTE-ACS cohorts with high penetration of DES platforms and agents more potent than clopidogrel, this effect was borderline (OR 1.241, 95% CI 0.901–1.709 – Figure 1 and OR 1.443, 95% CI 0.742–2.807 – Figure 2, respectively). Of all variables, the use of potent P2Y12 inhibitors was independently associated with the increase of major bleeding events (coefficient 0.743, 95% CI 0.133–1.354, P=0.017). Conclusions: Our updated results show that P2Y12 pretreatment was associated with the increased likelihood of major bleeding with this effect diminished in contemporary NSTE-ACS cohorts, although the latter could be attributed to presence of heterogeneity. The use of potent P2Y12 agents was a significant modifier of major bleeding. Taken together, routine pretreatment with P2Y12 inhibitors in NSTE-ACS increases the likelihood of major bleeding with this effect generally being enhanced by potent antiaggregation used, regardless of pretreatment utilization.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA